TY - JOUR
T1 - Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats
AU - Ariail, Kiley S.
AU - Bebo, Bruce F.
AU - Adlard, Kirsten
AU - Robey, Ian
AU - Burrows, Gregory
AU - Newman, Mark J.
AU - Todd, Charles W.
AU - Vandenbark, Arthur A.
AU - Offner, Halina
N1 - Funding Information:
The authors wish to thank Eva Niehaus for preparation of the manuscript. This work was supported by the Department of Veterans Affairs, and NIH grants NS23221 and NS23444.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.
AB - Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.
UR - http://www.scopus.com/inward/record.url?scp=0031986362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031986362&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(97)00150-3
DO - 10.1016/S0264-410X(97)00150-3
M3 - Article
C2 - 9607016
AN - SCOPUS:0031986362
SN - 0264-410X
VL - 16
SP - 99
EP - 108
JO - Vaccine
JF - Vaccine
IS - 1
ER -